CD30 +

About

Biomarker Type: Protein expression

Present: True

Marker: CD30

Unit: status

Equality: =

Value: Positive


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) CD30 + Anaplastic Large Cell Lymphoma Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Sensitivity (+) CD30 + Anaplastic Large Cell Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin, Dacarbazine, Doxorubicin, Vinblastine
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Cutaneous T-cell Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin, Cisplatin, Cytarabine, Etoposide
Sensitivity (+) CD30 + Cutaneous T-cell Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 + Hodgkin Lymphoma Brentuximab Vedotin
Sensitivity (+) CD30 +, HER2-negative Hodgkin Lymphoma Brentuximab Vedotin, Carboplatin, Etoposide, Ifosfamide
Sensitivity (+) CD30 + Hodgkin Lymphoma Bendamustine, Brentuximab Vedotin